Literature DB >> 3032089

Activity of (+)-cyclaradine (Sch 31172) against herpes simplex virus in vitro and in vivo.

J Schwartz, M Ostrander, N J Butkiewicz, M Lieberman, C Lin, J Lim, G H Miller.   

Abstract

(+)-Cyclaradine (Sch 31172) is the carbocyclic derivative of adenosine arabinoside (9-beta-D-arabinofuranosyladenine). Because it is not deaminated by deaminase in serum, as is adenosine arabinoside, (+)-cyclaradine is about 2 to 5 times more active in vitro against herpes simplex virus. (+)-Cyclaradine has in vitro activity nearly equivalent to that of phosphonoformate but is significantly less active than acycloguanosine (acyclovir; ACV), trifluorothymidine, or 9-(1,3-dihydroxy-2-propoxymethyl)guanine. The absolute ratios of in vitro activities are difficult to determine because of variability among virus strains, inoculum size, and dependence on the tissue culture cell line in which the comparative test is carried out. (+)-Cyclaradine is active against TK-, ACV-resistant mutants. In the guinea pig model of vaginal herpes simplex virus infection, (+)-cyclaradine is only slightly less active than ACV when both molecules are nearly equivalently bioavailable; thus, the large difference in activity seen in vitro is not reflected in this in vivo model system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032089      PMCID: PMC174644          DOI: 10.1128/AAC.31.1.21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

Authors:  J A Fyfe; P M Keller; P A Furman; R L Miller; G B Elion
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

2.  Carbocyclic arabinosyladenine, an adenosine deaminase resistant antiviral agent.

Authors:  R Vince; S Daluge
Journal:  J Med Chem       Date:  1977-04       Impact factor: 7.446

3.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

4.  Latent herpes simplex virus infection of mice. Infectious virus in homogenates of latently infected dorsal root ganglia.

Authors:  J Schwartz; W Whetsell; T S Elizan
Journal:  J Neuropathol Exp Neurol       Date:  1978-01       Impact factor: 3.685

5.  Interallelic complementation of mutants of herpes simplex virus deficient in deoxypyrimidine kinase activity.

Authors:  A T Jamieson; J H Subak-Sharpe
Journal:  Virology       Date:  1978-03       Impact factor: 3.616

6.  Growth of herpes simplex virus in transformed glial and neuronal cells in tissue culture: ultrastructural studies.

Authors:  J Schwartz; T S Elizan
Journal:  J Neuropathol Exp Neurol       Date:  1973-04       Impact factor: 3.685

7.  Metabolic studies with carbocyclic analogs of purine nucleosides.

Authors:  L L Bennett; P W Allan; D L Hill
Journal:  Mol Pharmacol       Date:  1968-05       Impact factor: 4.436

8.  Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus.

Authors:  E De Clercq; J Descamps; G Verhelst; R T Walker; A S Jones; P F Torrence; D Shugar
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

9.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

Review 10.  Vidarabine: a preliminary review of its pharmacological properties and therapeutic use.

Authors:  R Whitley; C Alford; F Hess; R Buchanan
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

View more
  1 in total

1.  Evaluation of (+)-cyclaradine-5'-esters as prodrugs for (+)-cyclaradine in animals.

Authors:  J Lim; J Schwartz; D Loebenberg; G H Miller; S Symchowicz; C Lin
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.